Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17629791 | 0.98 | DGAT1 (0.36) | DGAT1PARP1CA1CA2CA4 | |
| SCHEMBL15359952 | 0.85 | DGAT1 (0.32) | DGAT1PARP1CA1CA2 | |
| SCHEMBL1003390 | 0.82 | CES2 (0.44) | DGAT1PARP1CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL29810617 | 0.80 | CES2 (0.43) | DGAT1PARP1CA1CA2CA4 | |
| SCHEMBL811633 | 0.80 | PARP1 (0.45) | DGAT1PARP1HDAC1HDAC6POLB | |
| SCHEMBL614717 | 0.80 | MEN1 (0.39) | CA1CA2CA4HDAC1HDAC6 | |
| SCHEMBL12121150 | 0.78 | POLB (0.41) | DGAT1PARP1HDAC1HDAC6KDM4E | |
| SCHEMBL1317647 | 0.78 | DGAT1 (0.55) | DGAT1PARP1CA1CA2CA4 | |
| SCHEMBL3024877 | 0.78 | GRM2 (0.42) | DGAT1PARP1POLBPBRM1IDO1 | |
| SCHEMBL6192201 | 0.78 | KMT2A (0.39) | CA1CA2CA4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-19 | — | — | US | disclosed |
| CN-106687458-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2017-05-17 | — | — | CN | disclosed |
| EP-1871769-B1 | CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE. | ASTRAZENECA AB (SE) | 2017-02-22 | — | — | EP | disclosed |
| WO-2016046164-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| WO-2013161904-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | 味の素株式会社 (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-8304417-B2 | Crystalline forms of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline | ASTRAZENECA AB (SE) | 2012-11-06 | — | — | US | disclosed |
| US-20090099196-A1 | Chemical Process | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1871769-A2 | PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE,THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF | AstraZeneca AB (SE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006064217-A2 | PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| EP-0647217-B1 | 4-ACYLAMINOBENZAMIDES AND THEIR USE AS FUNGICIDES | ZENECA LTD (GB) | 1997-10-29 | — | — | EP | disclosed |
| EP-0647217-A1 | 4-ACYLAMINOBENZAMIDES AND THEIR USE AS FUNGICIDES. | ZENECA LTD (GB) | 1995-04-12 | — | — | EP | disclosed |
| CN-1090269-A | Mycocide | ZENECA LTD (GB) | 1994-08-03 | — | — | CN | disclosed |
| WO-1994000422-A2 | 4-ACYLAMINOBENZAMIDES AND THEIR USE AS FUNGICIDES | ZENECA LIMITED (GB) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099196-A1 | Chemical Process | CYP3A5, CYP3A43, CYP3A7 | DGAT1 2301/4885PARP1 419/4885CA1 2623/4885 |
| US-20170298052-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, PNPO, VASP | DGAT1 2806/4885PARP1 123/4885CA1 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.